Loading...
NPI 1750341202 · Reno, NV · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Steven Friedlander is a ophthalmology physician provider located in Reno, Nevada. This profile covers 23 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Steven Friedlander |
| Address | 610 Sierra Rose Dr |
| City | Reno |
| State | NV |
| ZIP | 89511 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | March 27, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.4M |
| Medicaid | $376.5K |
This provider’s billing is concentrated in Medicare by scale: Total Medicare revenue is $2.4M versus total Medicaid revenue of $376.5K, indicating Medicare is the dominant payer for this practice’s billed activity. The NPI has been enumerated since 2006-03-27 (~20 years ago), showing long tenure which is consistent with an established outpatient ophthalmology/retina practice.
Medicare revenue is highly concentrated in three injection/biologic codes: the precomputed top 3 Medicare codes account for 79.7% of the provider’s total Medicare revenue, driven by J0178 (49.5%), J2777 (23.9%), and J3590 (6.4%). This concentration signals that intravitreal biologic therapy is the central revenue driver for the Medicare book of business.
Medicaid billing is even more concentrated: the precomputed top 3 Medicaid codes account for 99.7% of this provider’s total Medicaid revenue, with J0178 alone representing $365.4K (97.1% of Medicaid revenue). In practical terms, the provider’s Medicaid volume is effectively dependent on aflibercept administrations (J0178), with the remainder split across a small number of ancillary retinal procedures.
The code mix and descriptions indicate a retina-focused ophthalmology operation: high-revenue biologic injections (J0178, J2777, J9035) combined with retina procedures (67028, 67036, 67041) and retinal imaging (92134, 92250) point to a practice organized around frequent intravitreal injections, diagnostic retinal imaging, and periodic surgical interventions. The presence of multiple surgical retina codes (e.g., 67036, 67108, 67041) alongside imaging codes suggests a service line that covers both medical retina and discrete surgical referrals.
Competitive standing is mixed by code: for Medicare, J0178 ranks #667 of 3204 providers nationally (79th percentile) and J2777 ranks #527 of 2039 providers nationally (74th percentile), characterizing the provider as a solid but not dominant national participant for those injection therapies. By contrast, retinal imaging codes show above-typical national volume — 92134 ranks #1145 of 26868 providers (96th percentile) and 92250 ranks #1062 of 25087 providers (96th percentile) — indicating the provider performs retinal imaging at a materially higher rate than most peers.
State-level Medicaid standing for the dominant Medicaid code is modest: J0178 ranks #4 of 6 providers in-state (40th percentile), so although J0178 drives nearly all Medicaid revenue here, the provider is not a leading aflibercept biller among Nevada Medicaid peers. Other Medicaid codes (67028, J9035, 92134) comprise only small shares of Medicaid revenue, reinforcing the provider’s dependence on a single high-revenue Medicaid drug code.
There are notable statistical outliers in the Medicare mix that merit attention: 99204 is classified as an "extreme outlier" (ranks #2666 of 227068 providers nationally, 99th percentile) indicating unusually high billed volume for hospital/clinic new-patient visits at that level, while several imaging codes are labeled "notably above typical" (92134 and 92250 at the 96th percentile) reflecting above-typical diagnostic throughput. These standing annotations suggest pockets of practice activity—new patient E/M and retinal imaging—that diverge from the provider’s otherwise injection-centered revenue profile.
Operationally, the raw counts reinforce a high-throughput injection practice: J0178 shows 1.7K Medicare claims and 412 Medicaid claims, and J2777 shows 20K Medicare claims, which—combined with modest average paid/claim figures for some injectable agents—suggests routine administration workflows and capacity for frequent intravitreal treatments. While percentile rankings for these codes are characterized as "typical, unremarkable volume" nationally, the absolute claim counts imply the practice manages substantial injection throughput alongside its diagnostic imaging and episodic surgical procedures.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
23 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,750 | $690 | $1.2M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 20,040 | $30 | $581.2K |
| J3590 | Unclassified biologics | 90 | $1,800 | $155.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,540 | $100 | $146.3K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 400 | $160 | $61.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,900 | $30 | $56.9K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 240 | $120 | $29.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 440 | $70 | $28.8K |
| J9035 | Injection, bevacizumab, 10 mg | 500 | $50 | $26.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 270 | $90 | $24.2K |
Showing 1–10 of 23
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
23 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 4 | 20 | 830 | $690 | $671.6K |
| J2777 | 4 | 10 | 7,020 | $30 | $616.8K |
| J3590 | 2 | 10 | 90 | $2,050 | $233.8K |
| 67028 | 4 | 30 | 670 | $90 | $72.3K |
| J7312 | 3 | 10 | 380 | $160 | $68.5K |
| 67108 | 2 | 10 | 20 | $1,100 | $24.3K |
| 67036 | 2 | 10 | 30 | $950 | $20.8K |
| 67042 | 6 | 10 | 20 | $1,090 | $20.7K |
| 67041 | 2 | 10 | 20 | $880 | $19.3K |
| 99214 | 1,887 | 3,610 | 110 | $80 | $19K |
Showing 1–10 of 23
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 410 | $890 | $365.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 210 | $30 | $6.4K |
| J9035 | Injection, bevacizumab, 10 mg | 170 | $20 | $3.3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 100 | $10 | $1.1K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 4 | 10 | 590 | $810 | $453.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 6 | 10 | 140 | $50 | $117.6K |
| J9035 | Injection, bevacizumab, 10 mg | 4 | 10 | 170 | $40 | $81.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 28 | 40 | 210 | $20 | $47.3K |
Other providers in the same ZIP code as Steven Friedlander, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.